🇺🇸 SEMAGLUTIDE in United States
4,488 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 4,488
Most-reported reactions
- Nausea — 862 reports (19.21%)
- Vomiting — 750 reports (16.71%)
- Diarrhoea — 537 reports (11.97%)
- Off Label Use — 362 reports (8.07%)
- Fatigue — 360 reports (8.02%)
- Weight Decreased — 360 reports (8.02%)
- Dyspnoea — 353 reports (7.87%)
- Drug Ineffective — 340 reports (7.58%)
- Dizziness — 288 reports (6.42%)
- Headache — 276 reports (6.15%)
SEMAGLUTIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SEMAGLUTIDE approved in United States?
SEMAGLUTIDE does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SEMAGLUTIDE in United States?
Marketing authorisation holder not available in our data.